AstraZeneca's Hypertension Drug Baxdrostat Nears FDA Approval
Event summary
- AstraZeneca's NDA for baxdrostat, a novel aldosterone synthase inhibitor, has been accepted for Priority Review by the FDA in the US.
- The FDA anticipates a PDUFA date during the second quarter of 2026, leveraging a Priority Review voucher.
- Phase III BaxHTN trial data, published in the New England Journal of Medicine, demonstrated a 15.7 mmHg reduction in systolic blood pressure with a 2mg dose of baxdrostat.
- AstraZeneca acquired CinCor Pharma in February 2023, triggering a $500 million contingent value right payment upon NDA submission.
The big picture
Hard-to-control hypertension affects a significant portion of the US population, representing a substantial unmet medical need. Baxdrostat’s novel mechanism of action addresses this need by targeting aldosterone, a key driver of hypertension, and offers a potential first-in-class treatment option. AstraZeneca's acquisition of CinCor Pharma demonstrates a strategic focus on expanding its cardiovascular portfolio and addressing high-burden diseases.
What we're watching
- Regulatory Risk
- The FDA's decision on baxdrostat will hinge on the BaxHTN trial data and could set a precedent for approval of novel aldosterone synthase inhibitors, impacting other companies in the pipeline.
- Market Adoption
- The success of baxdrostat will depend on physician adoption and patient access, given the existing landscape of antihypertensive medications and potential pricing pressures.
- Pipeline Expansion
- AstraZeneca’s broader clinical trial program for baxdrostat, including monotherapy and combination therapies, will reveal the drug’s full potential and impact on other cardiovascular and renal conditions.
Related topics